A Review of the Clinical Pharmacokinetics and Pharmacodynamics of Varenicline for Smoking Cessation
A Review of the Clinical Pharmacokinetics and Pharmacodynamics of Varenicline for Smoking Cessation
About this item
Full title
Author / Creator
Publisher
Cham: Springer International Publishing
Journal title
Language
English
Formats
Publication information
Publisher
Cham: Springer International Publishing
Subjects
More information
Scope and Contents
Contents
Varenicline tartrate (Chantix®/Champix®) is a selective partial agonist of the α
4
β
2
nicotinic acetylcholine receptor and is approved as an aid to smoking cessation. The usual oral dosage in adults is 1 mg twice daily for 12 weeks, with an initial titration week. Several clinical pharmacology studies have characterized the pharmacokin...
Alternative Titles
Full title
A Review of the Clinical Pharmacokinetics and Pharmacodynamics of Varenicline for Smoking Cessation
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_762576158
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_762576158
Other Identifiers
ISSN
0312-5963
E-ISSN
1179-1926
DOI
10.2165/11537850-000000000-00000
